Abstract
Examining postmortem tissue is the most direct way of evaluating the effect of antemortem drug use on the pathological processes believed to be important in Alzheimer's disease (AD). A small number of studies have recently been published in which data from human autopsy tissue and animal models provides important insight into the mechanisms by which anti-inflammatory (AI) agents may protect against AD. These indicate that certain classes of AI drugs may be capable of reducing the chronic inflammation which is consistently seen in AD brain tissue. In addition, a recent study using a transgenic mouse model of AD, suggests that AI therapy may also influence the accumulation of senile plaques and dystrophic neurites. The results of these and future postmortem studies will be invaluable in the development of optimum treatment strategies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
